As reported by alluvial plots (Figure 2 and Figure 3) by measuring CD26+LSCs at several time points during the study core (12 months), we observed fluctuating values of residual LSCs with great variability within each patient and between patients both in the subgroup that lost TFR (Figure 2) and in the 71 CML patients in sustained TFR (Figure 3). The gene discussed is DPP4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.